Drugs / Broncho-Vaxom
Broncho-Vaxom
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT05857930 | Jun 2023 → Sep 2026 expected | bronchial disorder | OM Pharma SA | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05064631 | Jan 2022 → Jun 2024 | asthma, respiratory tract infectious disorder | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2 | NCT05222516 | Dec 2021 → Jul 2023 | atopic eczema | OM Pharma SA | Terminated | No outcome recorded |
| Phase 2 | NCT04129931 | Dec 2019 → Feb 2025 | asthma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05588804 | Nov → Dec 2022 | respiratory tract infectious disorder | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT04496245 | Aug 2020 → Jun 2021 | COVID-19, viral respiratory tract infection | The University of Queensland | Completed | No outcome recorded |
| Phase 3 | NCT03047954 | Jul 2003 → Dec 2006 | atopic eczema | Vifor Pharma | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06655272 | Feb 2025 → Jan 2026 overdue | respiratory tract infectious disorder | Campus-Bio-Medico University | Recruiting | No outcome recorded |
| Phase 4 | NCT07178002 | Dec 2024 → Jan 2026 overdue | respiratory tract infectious disorder | Fondazione Policlinico Universitario Campus Bio-Medico | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05677763 | Dec 2022 → Mar 2026 overdue | lower respiratory tract disorder, respiratory tract infectious disorder | OM Pharma SA | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01968421 | Mar 2015 → Nov 2018 | bronchiectasis | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05044169 | Sep 2021 → Sep 2023 | nephrotic syndrome of childhood - steroid sensitive | Fang Deng | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05063149 Comparator | Jan 2022 → Dec 2025 overdue | asthma | Franciscus Gasthuis | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03243565 Comparator | Nov 2017 → May 2019 | adenoid hypertrophy, respiratory tract infectious disorder | Dr. Sami Ulus Children's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00733226 Comparator | Aug 2007 → Sep 2008 | asthma | Kecioren Education and Training Hospital | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Broncho-Vaxom | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05222516 ↗ |
| Known as | Bacterial Lysate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05064631 ↗ |
| Known as | Broncho-munal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05588804 ↗ |
| Known as | OM-85 | “OM 85 (lyophilized bacterial lysate) proved effective in increasing the immune response against bacteria in animal models.” NCT06655272 ↗6“OM 85 (lyophilized bacterial lysate) proved effective in increasing the immune response against bacteria in animal models.” NCT07178002 ↗ “Broncho-Vaxom adult capsules® (OM85)” NCT04496245 ↗ |
| Known as | OM-85 BV | “Drug: OM-85 BV” NCT01968421 ↗ |
| Known as | Vaxoral | “Effect of Vaxoral® (OM-85) on Frequency of Respiratory Tract Infections and Size of Adenoid Tissue in Preschool Children With Adenoid Hypertrophy” NCT03243565 ↗ |
| Modality | Other / unclassified | “OM-85 BV is an bacteria lysate” NCT00733226 ↗ |
| Route | Oral | “The children received one capsule per oral, OM-85 BV (3.5 mg) per day” NCT00733226 ↗ |